Catabasis Presents Positive Data From Part A Of The MoveDMD Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The World Muscle Society Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Catabasis is presenting positive data from Part A of the MoveDMD trial of edasalonexent for the treatment of Duchenne muscular dystrophy (DMD) at the World Muscle Society Congress. The World Muscle Society Congress is being held October 4 – October 8, 2016, in Granada, Spain, at the Palacio de Congresos de Granada.